3 Dividend Stocks Trading Near Their 52-Week Lows

CVS Health is identified as the preferred long-term dividend value idea among three stocks near 52-week lows, supported by a 2.7%+ yield, Q3 revenue growth of 10% to $81.2 billion, and a dividend payout increase of 21% since late 2021. Baxter has lost roughly half its value over 12 months and recorded a $3.1 billion Hill-Rom impairment, while pursuing business spinoffs and potential asset sales. L3Harris cut 2022 guidance amid inflation and supply-chain pressures and faces investor skepticism over its $4.7 billion Aerojet Rocketdyne acquisition, though its dividend yield is nearly 2.3%.

Analysis

The article’s apparent value signal is stale: each company’s strategic perimeter, capital allocation, and earnings base have changed materially since the referenced period. A 52-week-low screen plus a 2%-3% dividend yield is not sufficient evidence of downside protection; for BAX, the relevant question is whether post-separation leverage, stranded costs, and remaining medical-products margin can support both investment needs and distributions. Until current organic-growth, gross-margin, and free-cash-flow conversion data are refreshed, BAX is a restructuring watch item rather than a contrarian long.

CVS remains the most defensible defensive framework, but the investment debate is no longer simply recession resilience. The key swing factors are Medicare Advantage reimbursement/utilization, pharmacy-benefit-manager regulatory pressure, and whether healthcare-services assets earn above their acquisition cost of capital; deterioration in any of these can compress the conglomerate multiple despite stable revenue. A relative long CVS versus BAX can work if CVS demonstrates medical-cost-ratio stabilization and maintains cash conversion after debt service.

LHX’s strategic value rests on missile, space, communications, and propulsion exposure, but defense primes can underperform during robust budget narratives when fixed-price program charges, supplier inflation, or integration costs absorb incremental revenue. The more actionable comparison is LHX versus LMT: LHX requires evidence that acquired propulsion content improves segment margins and backlog conversion, while LMT offers a cleaner benchmark for defense-budget beta. Consensus may underappreciate that buyback suspension or lower capital returns can matter more to near-term equity returns than a favorable multi-year backlog.

Near-term catalysts are quarterly guidance, cash-flow conversion, and any revised capital-return targets; the 6-18 month catalyst is proof that acquired or separated assets improve return on invested capital. The thesis is falsified by another guidance reset, rising leverage without corresponding EBITDA growth, or persistent margin dilution after integration milestones.

Key Decisions for Investors

• No outright BAX long before reviewing current leverage, free-cash-flow guidance, and post-separation cost structure. Consider a starter position only after two consecutive quarters of organic growth and margin stabilization; exit on a renewed full-year FCF or earnings-guide cut.
• Watch for a 3-6 month pair: long CVS / short BAX, sized beta-neutral, if CVS reports stable medical-cost trends and reaffirmed cash-flow guidance while BAX misses margin or deleveraging milestones. Target a mid-single-digit relative return; stop if CVS faces a material reimbursement or utilization-driven guidance reset.
• Use LHX versus LMT as a tactical defense-relative trade rather than a broad sector long: go long LHX / short LMT only after LHX shows improving acquired-business margins and restored capital-return capacity. If integration charges persist or free cash flow misses plan, favor LMT as the cleaner quality exposure.
• Set earnings alerts for dividend coverage: a payout funded through incremental debt, materially reduced buybacks without deleveraging, or FCF conversion below management targets should override yield-based valuation arguments.